Alpha Cognition Announces CONVERGE Real-World Evidence on ZUNVEYL®(Benzgalantamine) Use in Long-Term Care
Alpha Cognition announced initial CONVERGE real-world evidence showing 79-81% of long-term care residents on ZUNVEYL reached a therapeutic dose versus 37-54% on generic AChEIs. ZUNVEYL residents also saw net decreases in concomitant medication-class burden across all eight classes evaluated, while generic AChEI residents saw net increases; titration comparisons were p<0.0001. The analysis is retrospective and unadjusted for confounders and does not establish causality, limiting how much commercial signal investors should draw.
Key figures
- Drug Name
- ZUNVEYL (benzgalantamine)
- Phase Of Trial
- Retrospective real-world evidence (CONVERGE, 180-day analysis)
- Titration comparison p value
- p<0.0001
- Therapeutic dose switchers zunveyl
- 80.7%
- Therapeutic dose switchers generics
- 54.0%
- Therapeutic dose all dose new to achei zunveyl
- 79.2%
- Therapeutic dose all dose new to achei generics
- 53.7%
- Therapeutic dose new to achei starting dose zunveyl
- 79.1%
- Therapeutic dose new to achei starting dose generics
- 37.3%
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.